Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (78)

I-01Annika Schneider

Physiologically based pharmacokinetic modeling – application for renal and hepatic impairment

Wednesday 10:10-11:40

I-02Johannes Schropp

Characterization of bispecific antibodies and the ternary complex including an optimal dosing strategy

Wednesday 10:10-11:40

I-03Pascal Schulthess

Frequency-domain derived optimisation of cell cycle specific cancer treatment

Wednesday 10:10-11:40

I-04Bernard Sebastien

Hypoglycemic risk kinetics modeling as patient achieving glucose control in insulin-naïve T2DM patients initiating glargine 300U/mL versus glargine 100U/mL

Wednesday 10:10-11:40

I-05Malte Selch Larsen

Impact of trial designs, study conditions and statistical methods on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors

Wednesday 10:10-11:40

I-06Jérémy Seurat

Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes

Wednesday 10:10-11:40

I-07Shringi Sharma

A Joint Model to Evaluate the Relationship between Lymph Node Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

Wednesday 10:10-11:40

I-08Dmitry Shchelokov

A semi-mechanistic model of targeted therapy for melanoma

Wednesday 10:10-11:40

I-09Yucheng Sheng

Item response theory modelling of motor scores to investigate feasibility of reducing proof-of-concept trial for Parkinson’s disease

Wednesday 10:10-11:40

I-10Christian Siebel

Consensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi process

Wednesday 10:10-11:40

I-11Alena Simalatsar

Personalised delivery rate computation for intravenously administered anesthetic using Kalman filter

Wednesday 10:10-11:40

I-12Erik Sjögren

Bridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole

Wednesday 10:10-11:40

I-13Mike K Smith

Implementing “best practice” in Pop PK modeling

Wednesday 10:10-11:40

I-14Tom Snowden

A comparison of two model reduction methodologies for a QSP bone biology system with denosumab dosing.

Wednesday 10:10-11:40

I-15Victor Sokolov

Evaluation of the utility and efficiency of MATLAB and R-based packages for the development of quantitative systems pharmacology models

Wednesday 10:10-11:40

I-16Eunjung Song

Bayesian estimation of parameters in the pharmacokinetic model

Wednesday 10:10-11:40

I-17Felix Stader

A population database for elderly to inform physiologically-based pharmacokinetic models considering anatomical, physiological and biological system parameters

Wednesday 10:10-11:40

I-18Konstantinos Stamatopoulos

A Population based PBPK Modelling for the Prediction of Bile Salts Disposition within GI Luminal Fluids – Towards a Mechanistic Bile Salts Model

Wednesday 10:10-11:40

I-19Andrew Stein

Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems

Wednesday 10:10-11:40

I-20Mark Stroh

Customizing the distribution of a masked, tumor-activated antibody with quantitative systems pharmacology

Wednesday 10:10-11:40

I-21Sabine Stuebler

Systems biology model of the mucosal immune system in the context of inflammatory bowel disease

Wednesday 10:10-11:40

I-22Claudia Suenderhauf

The Basel Phenotyping Capsule as a tool for Quantifying Human metabolism in vivo – a tool to personalize physiological and semiphysiological Models

Wednesday 10:10-11:40

I-23Elin Svensson

Meta-analysis of rifampicin exposure and mortality in three randomized controlled phase II tuberculosis meningitis trials

Wednesday 10:10-11:40

I-24Robin Svensson

The value of model-based therapeutic drug monitoring in tuberculosis treatment – optimized target for rifampicin

Wednesday 10:10-11:40

I-25

Model-based analysis for the screening and ranking of compounds against Plasmodium Falciparum

Wednesday 10:10-11:40

I-26

Population Pharmacokinetics of Tacrolimus in Pediatric Patients having undergone kidney, liver or bowel/liver transplantation.

Wednesday 10:10-11:40

I-27Lénaïg Tanneau

Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect

Wednesday 10:10-11:40

I-28Sonya Chapman

Dose Fractionation Study Design and PK/PD Model Analysis to Establish the Quantitative Pharmacology of Selective Aurora A Kinase Inhibition by Compound X and LY3295668

Wednesday 10:10-11:40

I-29Nadia Terranova

The CICIL tool: a Java-based user-friendly application for the analysis of individual tumor size lesion dynamics

Wednesday 10:10-11:40

I-30Adrien Tessier

Population pharmacokinetics in adults and model-based extrapolation and dose selection in the paediatric DMD population for drug S48168/ARM210

Wednesday 10:10-11:40

I-31

Population pharmacokinetic and exposure-lymphocyte analysis of FTY720 (Fingolimod/Gilenya) in pediatric patients with Multiple Sclerosis

Wednesday 10:10-11:40

I-32Pauline Themans

Prediction of meropenem systemic and infection site exposure and open-loop control strategy for optimal drug dosing: a PBPK approach

Wednesday 10:10-11:40

I-33Tjokosela Tikiso

TB/HIV co-treatment with superboosted lopinavir lowers abacavir concentrations in children

Wednesday 10:10-11:40

I-34Tom Haber

DiffMEM: an open-source package for high-performance pharmacometric model estimation

Wednesday 10:10-11:40

I-35Elena Tosca

In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone.

Wednesday 10:10-11:40

I-36Kota Toshimoto

Application of virtual clinical studies to predict the effect of inter-individual differences on the drug/metabolites exposures in the blood and target organs leading to different pharmacological and toxicological effect

Wednesday 10:10-11:40

I-37Pauline Traynard

New library of time-to-event (TTE) models for the MonolixSuite and application to two experimental data sets

Wednesday 10:10-11:40

I-38Iñaki F. Trocóniz

An immune quantitative framework for Hepatitis B viral infection

Wednesday 10:10-11:40

I-39Denise Feick

Physiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone

Wednesday 10:10-11:40

I-40Sami Ullah

Population pharmacokinetic analysis of piperacillin in acute haemorrhagic stroke patients – a cerebral microdialysis study

Wednesday 10:10-11:40

I-41Chakradhara Rao Satyanarayana Uppugunduri

Population pharmacokinetic model for individualized busulfan dosing in children: Annexation to the existing vast list of PopPK models for performance evaluation

Wednesday 10:10-11:40

I-42Piet van der Graaf

Systems pharmacology modelling of the alternative pathway to study target suitability

Wednesday 10:10-11:40

I-43Louvina van der Laan

Pharmacokinetics of intracellular stavudine-triphosphate in children after reduced-dose: can we improve stavudine’s safety profile?

Wednesday 10:10-11:40

I-44Michiel Van Esdonk

Population pharmacokinetic/pharmacodynamic analysis of multiple nociceptive pain models following a single oral pregabalin dose administration to healthy subjects

Wednesday 10:10-11:40

I-45Erno van Schaick

Simulations of the paliperidone pharmacokinetics of intramuscular long-acting injectable microsuspensions of paliperidone palmitate in rats using a mechanistic model

Wednesday 10:10-11:40

I-46Tamara van Steeg

Development of a mathematical model to elucidate the cross-linking of GSK-057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality.

Wednesday 10:10-11:40

I-47Rob van Wijk

Nanoscale blood sampling from zebrafish larvae for the estimation of distribution volume and absolute clearance

Wednesday 10:10-11:40

I-48Marc Vandemeulebroecke

Graphical Principles Cheat Sheet

Wednesday 10:10-11:40

I-49Diego Vera-Yunca

Disease modelling of repeated acute attacks in an acute intermittent porphyria mouse model

Wednesday 10:10-11:40

I-50Swantje Völler

Use of second-to-second physiological monitoring data for continuous evaluation of pharmacotherapy in preterm infants: an application to the respiratory stimulant doxapram

Wednesday 10:10-11:40

I-51Veronika Voronova

Using a physiologically-based QSP model to simulate the effects of perturbations of the enterohepatic circulation of bile acids

Wednesday 10:10-11:40

I-52Johan Wallin

Validation of Xenograft Dose Predictions for Clinical Efficacy in NSCLC

Wednesday 10:10-11:40

I-53Evan Wang

Model-based assessment of QT interval correction methods

Wednesday 10:10-11:40

I-54Shijun Wang

A comparison between nonlinear mixed effects and naïve pooled data methods in population PK model selection

Wednesday 10:10-11:40

I-55Roeland Wasmann

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies

Wednesday 10:10-11:40

I-56Sebastian Weber

Supporting drug development as a Bayesian in due time?!

Wednesday 10:10-11:40

I-57Sebastian Wicha

Handling inter-occasion variability in model implementation for Bayesian forecasting: A comparison of methods and metrics.

Wednesday 10:10-11:40

I-58Mélanie Wilbaux

Risk score based on survival multivariate analysis of baseline patients’ characteristics reduces variability in a PKPD model of tumor growth inhibition

Wednesday 10:10-11:40

I-59Justin Wilkins

Population pharmacokinetic analysis of M7824 (MSB0011359C) in different cancer types

Wednesday 10:10-11:40

I-60Francis Williams Ojara

A time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapy

Wednesday 10:10-11:40

I-61Dan Wright

Identifying systematic bias in model predictions

Wednesday 10:10-11:40

I-62Liviawati Wu

Population Pharmacokinetics and Dosing Simulation of JNJ-64155806 (AL-794) in Healthy Volunteers

Wednesday 10:10-11:40

I-63Gudrun Wuerthwein

Population pharmacokinetics for PEGylated asparaginase Oncaspar® in children with ALL: differences between protocol parts and predictivity

Wednesday 10:10-11:40

I-64Xia Li

Population pharmacokinetics of ciprofloxacin in critically ill patients-a covariate analysis

Wednesday 10:10-11:40

I-65Feifan Xie

A model-based analysis of the kinetics of leukocytes in stage III ovarian cancer patients treated with neo-adjuvant chemotherapy, cytoreductive surgery and cisplatin-based intraperitoneal chemoperfusion

Wednesday 10:10-11:40

I-66James Yates

Structural Identifiability for Mathematical Pharmacology: Models of myelosuppression

Wednesday 10:10-11:40

I-67Jinqiu Yin

Optimizing treatment of cephalosporin-resistant pneumococcal meningitis

Wednesday 10:10-11:40

I-68Gunnar Yngman

Linearization of full random effects modeling (FREM) for time-efficient automatic covariate assessment

Wednesday 10:10-11:40

I-69Jurij Aguiar Zdovc

The expression of ABCB1 gene influences the PK of rivaroxaban – a PK/PD study in patients with the total hip or knee arthroplasty

Wednesday 10:10-11:40

I-70Nan Zhang

Creation of Pharmacometric Framework to Evaluate Clinical Trial Data on Predictive Biomarkers

Wednesday 10:10-11:40

I-71Ying Zhang

Exposure–Response Model and Development of a Shiny App of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients with Hereditary Angioedema (HAE)

Wednesday 10:10-11:40

I-72Fan Zhang

Structural and Practical Considerations in the Development of a Parent-metabolite Model

Wednesday 10:10-11:40

I-73

Population pharmacokinetic/pharmacodynamic modeling of plasma lyso-sphingomyelin response to enzyme replacement therapy olipudase alfa in patients with acid sphingomyelinase deficiency

Wednesday 10:10-11:40

I-74Li Zhang

Mechanism-based Population PK/PD modeling of T lymphocytes Depletion and Repopulation Following Treatment with anti-CD52 Antibody GLD52 in Patients with Progressive Multiple Sclerosis

Wednesday 10:10-11:40

I-75Chenyan Zhao

Quantification and prediction of the combined effect of minocycline and polymyxin B on multidrug-resistant Klebsiella pneumoniae

Wednesday 10:10-11:40

I-76Meng Zhaoling

Real World Evidence and Model-informed Drug Development – an antidiabetic drug cardiovascular outcome case study

Wednesday 10:10-11:40

I-77Yi Zheng

Effect of pregnancy on raltegravir free concentrations

Wednesday 10:10-11:40

I-78Xiao Zhu

Application of pharmacometrics to stimulus response models to describe signalling profiles of the cannabinoid-1 receptor

Wednesday 10:10-11:40